At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Immunoglobulin for Women With Unexplained Secondary Recurrent Miscarriage
In Brief
A Phase 3 clinical trial evaluating Intravenous immunoglobulin and Human albumin for Secondary Recurrent Miscarriage. Completed, enrolled 82 participants across 1 site.
Detailed Summary
The investigators want to test whether infusions of intravenous immunoglobulin - a blood product known to modify immune responses - in early pregnancy will increase the chance of a subsequent live birth in women with three or more miscarriages after a birth and a total of at least four miscarriages. This will be done in a trial where 82 patients will be randomly allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.
Study Details
Timeline
Interventions
Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week